In patients receiving conventional treatment, prognosis varies among PTCL subtypes: ALK-positive ALCL has the best 5-year overall survival (OS) of >70%, whereas ATLL has the worst 5-year OS of <20% (6), (7). Here, ALK is linked to adult T-cell leukemia/lymphoma.